SCHEDULE: FMR LLC Discloses 3.2% Stake in VOR BIOPHARMA INC

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 1,539,670 shares of VOR BIOPHARMA INC common stock, representing 3.2% of the class.

Summary

• FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, indicating their beneficial ownership of VOR BIOPHARMA INC common stock.
• The filing, dated March 31, 2026, reports a total of 1,539,670 shares beneficially owned.
• This holding represents 3.2% of the total outstanding shares of VOR BIOPHARMA INC's common stock.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an investment company (IN).
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership by a major financial entity, providing information on shareholding but not indicating any immediate positive or negative developments for the company.

Positives

• FMR LLC and Abigail P. Johnson, significant financial entities, hold a notable stake in VOR BIOPHARMA INC, suggesting confidence in the company's prospects.
• The disclosure confirms that the shares are held in the ordinary course of business, implying a standard investment strategy rather than a hostile takeover attempt.

Risks

• While not explicitly stated as a risk, any significant change in FMR LLC's or Abigail P. Johnson's holdings could impact VOR BIOPHARMA INC's stock price due to the size of the stake.
• The filing does not provide details on the specific investment strategy or reasons for acquiring the stake, leaving potential future shifts in ownership uncertain.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future performance of VOR BIOPHARMA INC. It solely reports current beneficial ownership.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares."
• "Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and indicate significant, but typically passive, ownership stakes. The 3.2% holding by FMR LLC and Abigail P. Johnson suggests they are a substantial, though not controlling, shareholder in VOR BIOPHARMA INC, aligning with typical investment patterns in the biopharmaceutical sector where institutional ownership is prevalent.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding significant institutional ownership, which can influence investor confidence. Changes in FMR LLC's holdings could impact share price.
• Management: The presence of a substantial institutional investor like FMR LLC may encourage adherence to strong corporate governance practices.
• Creditors: Stable institutional ownership can be seen as a positive indicator of the company's long-term viability.

Next Steps

• Monitor future filings by FMR LLC and Abigail P. Johnson for any changes in their beneficial ownership of VOR BIOPHARMA INC.
• Observe VOR BIOPHARMA INC's stock performance and company announcements for potential impacts related to institutional investor activity.

Key Dates

Keywords

VOR BIOPHARMA INC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Company, Holding Company